It seems obese breast cancer patients are frequently underdosed when it comes to chemotherapy.
It seems obese breast cancer patients are frequently underdosed when it comes to chemotherapy.
Researchers reviewed data from four randomized trials of the International Breast Cancer Study Group assessing the use of adjuvant classical chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil in premenopausal women with node-positive breast cancer.
They found that 39% of obese women received less than 85% of the chemotherapy dose specified by the protocol versus 16% of women with normal or intermediate body mass index. While this didn't significantly compromise outcome in the women with estrogen-receptor (ER)–positive disease, reducing the dose of chemotherapy was associated with a significantly worse outcome in the obese women with ER-negative cancer in terms of disease-free survival (total population hazards ratio ≥ 85% vs. <85%, 0.68, 95% CI; 0.54–0.86, P=0.0013) and overall survival (0.72, 0.56-0.94, P=0.0142).
A Legacy of Excellence: Reflecting on the Final Print Edition of Contemporary OB/GYN
April 25th 2025Marking the end of an era and the beginning of a new chapter, the final print edition of Contemporary OB/GYN celebrates over 50 years of evidence-based guidance and unwavering support for clinicians.
Read More